DrugPatentWatch Database Preview
Drugs in Development Information for AF-219
» See Plans and Pricing
What is the drug development status for AF-219?
AF-219 is an investigational drug.
There have been 14 clinical trials for AF-219.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2012.
The most common disease conditions in clinical trials are Cough, Fibrosis, and Pulmonary Fibrosis. The leading clinical trial sponsors are Afferent Pharmaceuticals, Inc., Celerion, and [disabled in preview].
There are fifteen US patents protecting this investigational drug and one hundred and thirty international patents.
Summary for AF-219
| US Patents | 15 |
| International Patents | 130 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 25 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2012-03-01) |
| Vendors | 20 |
Recent Clinical Trials for AF-219
| Title | Sponsor | Phase |
|---|---|---|
| A Multiple-Dose Pharmacokinetics Study of Three AF-219 Formulations | Afferent Pharmaceuticals, Inc. | Phase 1 |
| A 12-Week Study in Subjects With Refractory Chronic Cough | Afferent Pharmaceuticals, Inc. | Phase 2 |
| An 8-Week Refractory Chronic Cough Study | Afferent Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for AF-219
Top disease conditions for AF-219
Top clinical trial sponsors for AF-219
US Patents for AF-219
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AF-219 | Start Trial | Methods and compositions for treating diseases and conditions | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | Start Trial |
| AF-219 | Start Trial | Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | Start Trial |
| AF-219 | Start Trial | Methods and compositions for treating diseases and conditions | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | Start Trial |
| AF-219 | Start Trial | Diaminopyrimidines as P2X.sub.3 and P2X.sub.2/3 antagonists | Roche Palo Alto LLC (Palo Alto, CA) | Start Trial |
| AF-219 | Start Trial | Process for synthesis of phenoxy diaminopyrimidine derivatives | Roche Palo Alto LLC (Palo Alto, CA) | Start Trial |
| AF-219 | Start Trial | Methods of using diaminopyrimidine P2X.sub.3 and P2X.sub.2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | Roche Palo Alto LLC (Palo Alto, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AF-219
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AF-219 | European Patent Office | EP3164132 | 2034-07-03 | Start Trial |
| AF-219 | World Intellectual Property Organization (WIPO) | WO2016004358 | 2034-07-03 | Start Trial |
| AF-219 | Australia | AU2014308606 | 2033-08-23 | Start Trial |
| AF-219 | Canada | CA2921395 | 2033-08-23 | Start Trial |
| AF-219 | Chile | CL2016000400 | 2033-08-23 | Start Trial |
| AF-219 | Chile | CL2018002137 | 2033-08-23 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
